Tag: Eli Lilly

Browse all articles tagged with “Eli Lilly”.

1 article

Retatrutide: The Triple Agonist Setting New Records in Obesity Research

A research-focused overview of retatrutide (LY3437943), the investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly that achieved 23.7% body weight reduction in Phase 2 trials, the largest ever recorded in an obesity trial.

2026-03-06·15 min read

Retatrutidetriple agonistGIPGLP-1glucagonobesitymetabolic healthEli Lilly

←Back to blog

For informational purposes only. Not medical advice. Always consult with qualified healthcare professionals.